Keywords: tkt, 1st-qtr, losses, widen, transkaryotic, therapies, drugmaker

TKT's 1st-qtr losses widen 51%

Article | 16 May 2005

Transkaryotic Therapies, a US drugmaker focused on rare diseases, has reported a 2005 first-quarter net loss of $21.7 million, or $0.62 per share, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Shire

Go to company listing